Please login to the form below

Not currently logged in
Email:
Password:

lumateperone

This page shows the latest lumateperone news and features for those working in and with pharma, biotech and healthcare.

Intra-Cellular soars on FDA approval of schizophrenia drug

Intra-Cellular soars on FDA approval of schizophrenia drug

Shares in the company rocketed over 178% yesterday as the news broke, after the FDA approved Caplyta (lumateperone) as a treatment for schizophrenia in adults.

Latest news

  • Intra-Cellular plans schizophrenia filing in 2018 Intra-Cellular plans schizophrenia filing in 2018

    Says lumateperone could provide additional benefits over existing treatments. US biotech company Intra-Cellular Therapies says it could file its lead drug lumateperone for schizophrenia as early as next year after ... Lumateperone is backed by two phase

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Iguazu

Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...

Latest intelligence

Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...

Infographics